Cellular interplay in pulmonary arterial hypertension: Implications for new therapies  by Nogueira-Ferreira, Rita et al.
Biochimica et Biophysica Acta 1843 (2014) 885–893
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrReviewCellular interplay in pulmonary arterial hypertension: Implications for
new therapiesRita Nogueira-Ferreira a,b,⁎, Rita Ferreira a, Tiago Henriques-Coelho b
a QOPNA, Department of Chemistry, University of Aveiro, Aveiro, Portugal
b Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Porto, PortugalAbbreviations: 5-HT, serotonin; 5-HT1B, serotonin type
type 2A receptor; 5-HT2B, serotonin type 2B receptor; 5-H
adenosine diphosphate; ATP, adenosine triphosphate; AV
BMP, bone morphogenetic protein; BMPRII, bone morph
II; cAMP, cyclic adenosine monophosphate; cav-1, cave
blockers; cGMP, cyclic guanosine monophosphate; DNA
extracellular matrix; ECs, endothelial cells; eNOS, end
EPCs, endothelial progenitor cells; ET-1, endothelin-1; ETA
ETB, endothelin-1 type B receptor; FKN, fractalkine; HA, hy
line; MMPs, matrix metalloproteinases; mRNA,messenger
tinamide adenine dinucleotide phosphate; NO, nitric ox
endothelial cells; PAH, pulmonary arterial hypertension
inhibitor-1; PASMCs, pulmonary artery smooth muscle c
type 5; PDGF, platelet-derived growth factor; PGI2, pro
upon Activation, Normal T-cell Expressed and Secreted; R
muscle cells; SM-MHC, smooth muscle-myosin heavy
N-ethylmaleimide-sensitive factor association protein
TASK-1, two pore-related acid-sensitive potassium ch
growth factor-β; TNF-α, tumor necrosis factor-α; t-PA,
TXA2, thromboxane A2; VDCC, voltage-dependent calciu
muscle actin
⁎ Corresponding author at: Chemistry Department, U
Santiago, 3810-193 Aveiro, Portugal. Tel.: +351 2343707
E-mail address: rmferreira@ua.pt (R. Nogueira-Ferreir
0167-4889/$ – see front matter © 2014 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbamcr.2014.01.030a b s t r a c ta r t i c l e i n f oArticle history:
Received 12 August 2013
Received in revised form 23 January 2014
Accepted 24 January 2014
Available online 31 January 2014
Keywords:
Endothelial cell
Inﬂammation
Smooth muscle cell
Thrombosis
Vascular remodeling
VasoconstrictionPulmonary arterial hypertension (PAH) is a complex and multifactorial disease characterized by vascular
remodeling, vasoconstriction, inﬂammation and thrombosis. Although the available therapies have
resulted in improvements in morbidity and survival, PAH remains a severe and devastating disease with
a poor prognosis and a high mortality, justifying the need of novel therapeutic targets. An increasing num-
ber of studies have demonstrated that endothelial cells (ECs), smoothmuscle cells (SMCs) and ﬁbroblasts of
the pulmonary vessel wall, as well as platelets and inﬂammatory cells have a role in PAH pathogenesis. This
review aims to integrate the interplay among different types of cells, during PAH development and progres-
sion, and the impact of current therapies in cellular modulation. The interplay among endothelial cells,
smooth muscle cells and ﬁbroblasts present in pulmonary vessels wall, platelets and inﬂammatory cells is
regulated by several mediators produced by these cells, contributing to the pathophysiologic features of
PAH. Current therapies are mainly focused in the pulmonary vascular tone and in the endothelial dysfunc-
tion. However, once they have not been effective, novel therapies targeting other PAH features, such as in-
ﬂammation and platelet dysfunction are emerging. Further understanding of the interplay among different
vascular cell types involved in PAH development and progression can contribute to ﬁnd novel therapeutic
targets, decreasing PAH mortality and morbidity in the future.
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Pulmonary arterial hypertension is a progressive and life-threatening
disease,multifactorial in nature [1,2]. Although the “trigger” that leads to
the disease is still unknown, a complex interplay among different types
of cells occurs andmultiple alterations are veriﬁed: (i) intimal hyperpla-
sia; (ii) medial hypertrophy and hyperplasia; (iii) adventitia prolifera-
tion; (iv) neointima formation and (v) occurrence of plexiform lesions.
In addition, these changes are accompanied by vasoconstriction, local in-
ﬂammation and thrombosis in situ [3–6].
Endothelial cells, located in the inner layer of the pulmonary artery
wall, have several O2-sensing mechanisms, including O2-sensitive
NADPHoxidases, endothelial nitric oxide synthase, and hemeoxygenases
[7,8]. Vascular smoothmuscle cells, located in themedial layer, havemul-
tiple stretch-sensing mechanisms, and are able to convert a mechanical
stimulus into an intracellular signal that leads to modulation of gene ex-
pression and cellular function, such as contraction, proliferation, apoptosis
and migration [9]. Fibroblasts, present in the adventitial compartment,
may be considered the principal injury-sensing cells. Theymay experience
functional changes due to stimuli such as vascular injury (Fig. 1) [10].
Table 1
Current and novel therapies for pulmonary arterial hypertension.
Current therapies Novel therapies
Endothelial cells
Prostacyclin analogs Rho kinase inhibitor
Epoprostenol Fasudil
Treprostinil
Iloprost
Endothelin-1 receptor antagonists Dual endothelin-1 receptor antagonist
Bosentan Macitentan
Ambrisentan Pyruvate dehydrogenase kinase inhibitor
Dichloroacetate
Endothelial progenitor cells
Smooth muscle cells
Phosphodiesterase inhibitors Soluble guanylate cyclase stimulator
Sildenaﬁl Riociguat
Tadalaﬁl
Calcium channel blockers Prostacyclin receptor agonist
Nifedipine Selexipag
Diltiazem
Amlodipine
Fibroblasts
Elastase inhibitors
Inﬂammatory cells
Rapamycin
Tryptolide
Thymulin
Platelets
Thromboxane synthesis inhibitors
Ozagrel
Furegrelate
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processes, the next points intend to detail various aspects of the contribu-
tion of these cell types to development and progression of PAH aswell as
of platelets and inﬂammatory cells. Themediators that regulate the inter-
play between these distinct cell types during PAH development and pro-
gression will also be analyzed envisioning novel therapeutic targets.
2. Endothelial cells
2.1. Role in pathophysiology of PAH
Endothelial damage is a key initial event in PAH. Although themech-
anisms that mediate this damage are largely unknown, insults such as
chronic hypoxia, inﬂammation, viral infection, mechanical stretch or
shear stress, can activate the endothelial apparatus and induce cell apo-
ptosis [11]. The death of ECs leads to the appearance of apoptotic-
resistant and hyper-proliferative ECs, contributing to the vascularFig. 1. “Sensing” mechanisms in the different layers of the pulmonary artery wall. Endo-
thelial cells of the intima are equipped with mechanisms to sense differences in the oxy-
gen supply. Medial smooth muscle cells have multiple stretch-sensing mechanisms that
participate in the modulation of their functions. Fibroblasts, present in the adventitia,
are considered the principal injury-sensing cells.remodeling [12]. Endothelial cells not only contribute to the vascular re-
modeling linked to PAH development, but also regulate the related va-
soconstriction and thrombosis processes, through the production and
release of several mediators [2].
Endothelial cell migration and proliferation were thought to be re-
sponsible for the regeneration of injured endothelium. However, addi-
tional mechanisms were shown to replace the denuded or injured
arteries. It has been reported that endothelial progenitor cells (EPCs)
exert important functions in repairing and maintaining the integrity of
the endothelial monolayer by replacing denuded parts of the artery
[13]. After several pre-clinical studies demonstrate the beneﬁcial effects
of EPC administration, which was translated into a decrease of right
ventricle systolic pressure, aswell as a decrease in pulmonary and cardi-
ac remodeling [14], clinical trials were performed. Autologous EPC ad-
ministration in adult and pediatric idiopathic PAH patients showed an
improvement on pulmonary hemodynamics and exercise capacity
[15,16]. These results contrast with the ﬁnding that EPCs can contribute
to PAH-related vascular remodeling [17]. However, given the promising
results observed in clinical studies, the use of EPCs as a therapeutic op-
tion continues to be investigated. The results of the clinical trial PH (pul-
monary hypertension) and Cell Therapy (PHACeT trial; ClinicalTrials.gov
Identiﬁer: NCT00469027), performed with the aim of evaluating the
safety of administering autologous progenitor cells transduced with
eNOS in idiopathic PAH patients are awaited. Furthermore, a combined
therapy with autologous bone marrow-derived EPCs and sildenaﬁl (a
phosphodiesterase type 5 inhibitor) showed a superior efﬁcacy than ei-
ther bonemarrow-derived EPCs or sildenaﬁl alone in preventingmono-
crotaline (MCT)-induced PAH [18]. This combined therapy successfully
abolished PAH-induced hemodynamic impacts on the right ventricle.
Despite these encouraging results, it is yet unclearwhat is the EPCmech-
anism of action in PAH treatment. In this setting, a study reported that
EPC infusion preventedMCT-induced PAH in athymic nude rats through
a mechanism that requires the presence of natural killer cells [19].
2.2. Intracellular pathways modulated by PAH
The increase of endothelial cell permeability seems to have a huge
contribution to PAH pathogenesis [20]. Stimuli that activate RhoA/
ROCK, like thrombin, increase endothelial permeability. Stimuli that
stimulate Rac1/p21-activated kinase, like prostacyclin (PGI2), promote
barrier integrity [20,21]. The net effect of EC permeability favors the re-
lease of mediators like endothelin-1 (ET-1), nitric oxide (NO), PGI2 and
thromboxane-A2 (TXA2) on SMCs and platelets. In addition, endothelial
dysfunction in PAH can be reﬂected by a reduction in vasodilators/
growth inhibitors like NO and PGI2, and an increase in vasoconstrictors/
co-mitogens like ET-1 and TXA2 [20].
Another pathway that seems to contribute to EC permeability is the
bone morphogenetic protein (BMP) signaling pathway. Recently, the
loss of bone morphogenetic protein type II receptor (BMPRII) in ECs
was reported to promote the extravasation of leucocytes into the pul-
monary artery wall, increasing the susceptibility to inﬂammation [22].
Bonemorphogenetic proteins are members of the transforming growth
factor-β (TGF-β) family and signal via BMP type I and II receptors,which
are serine/threonine kinase transmembrane receptors. This interaction
with the receptors usually activates Smad1/5/8 that form complexes
with Smad4 and translocate to the nucleus, regulating gene expression
through the interactionwith transcription factors. Besides the canonical
Smad signaling, non-Smad pathways, such as the MAPK (mitogen-
activated protein kinase), can also be involved [23,24]. As it is known,
several gene mutations that lead to BMPRII loss of function have been
associated to heritable PAH [25,26]. However, BMPRII expression is re-
duced in the pulmonary vasculature of patients with heritable and idio-
pathic PAH, independently of whether they present or not the BMPRII
genemutation [27]. In ECs, BMPRII activation seems topromote cell pro-
liferation, migration and survival [28,29]. Loss of BMPRII function in
these cells was reported to induce apoptosis, contributing to the
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ly, a study reported that BMPRII ligands, BMP2 and BMP4, stimulate
eNOS (endothelial nitric oxide synthase) activity in PAECs (pulmonary
artery ECs), inducing NO synthesis. Furthermore, eNOS activity stimula-
tion was shown to be dependent on protein kinase A activation and
BMP-stimulated PAEC migration needs eNOS activity. Importantly,
BMP2 and BMP4 failed to stimulate eNOS phosphorylation/activation
in PAECs collected from PAH patients with BMPRII genemutations [30].
Endothelial cell mitochondrial metabolism is also affected in PAH. A
shift from oxidative phosphorylation to glycolysis was reported [1]. Xu
et al. [31] veriﬁed, through positron tomography scan, a signiﬁcantly
higher uptake of glucose in PAECs from patients with idiopathic PAH
compared with ECs from controls. In addition, they demonstrated that
oxygen consumption, the number of mitochondria per cell and the mi-
tochondrial DNA content of idiopathic PAH endothelial cells were
lower in comparison with ECs from control patients.
Alterations in the intracellular trafﬁcking were also reported in PAH
[32]. Histological and electron microscopy studies highlighted enlarged
endoplasmic reticulum and Golgi stacks in pulmonary arterial lesions in
human and in experimental (hypoxia andMCT) PAH [33,34]. In addition,
the loss of the cell surface raft/caveolar protein caveolin-1 (cav-1) in ECs
in MCT-induced PAH was shown [35]. Monocrotaline and hypoxia seem
to disrupt the molecular machinery of vesicular trafﬁcking at the level of
Golgi tethers, SNAPS (soluble ATPase N-ethylmaleimide-sensitive factor
association proteins) and SNARES (SNAP receptors) (Golgi blockade
hypothesis) [36,37]. This disruption seems to result in the trapping of
cav-1 in theGolgi of ECs,with consequent intracytoplasmic sequestration
of eNOS and thus, reduction of NO production [36].
Currently, the endothelial dysfunction is a primary therapeutic tar-
get in PAH, being used drugs such as prostacyclin analogs, endothelin-
1 receptor antagonists and phosphodiesterase type 5 (PDE-5) inhibitors
to counteract this abnormality [38]. The ﬁrst PGI2 synthetic analog ap-
proved by the FDA was intravenous epoprostenol. Although being to
date the only PAH therapy that was associated with a mortality beneﬁt
in a randomized clinical trial, epoprostenol administrationmight lead to
catheter infections [38]. To overcome this, a more stable formulation of
epoprostenol became recently available [39,40]. Treprostinil (subcuta-
neous, intravenous and inhaled) and iloprost (inhaled) were approved
as PGI2 analogs, also with some limitations. In the case of subcutaneous
treprostinil, infusion site pain occurs in the majority of patients and in-
haled iloprost needs to be administrated 6 to 9 times daily, up to 15min
each [38,41]. Currently, a phase III clinical trial is underway to evaluate
the effect of an oral formulation of a PGI2 receptor agonist named
selexipag (GRIPHON trial; ClinicalTrials.gov Identiﬁer: NCT01106014).
Approved therapies targeting ET-1 pathway include the dual ET-1 re-
ceptor antagonist bosentan and the selective ETA receptor antagonist
ambrisentan, both available in oral formulations. In the case of
bosentan, regular liver function tests are needed, once it is associated
with an increased risk of liver dysfunction [38,41,42]. Macitentan is a
new oral dual ET-1 receptor antagonist that presents an increased efﬁ-
cacy due to its high lipophilicity [38,43]. Sildenaﬁl and tadalaﬁl are
oral PDE-5 inhibitors approved for the treatment of PAH. Side effects in-
clude headache, ﬂushing, dyspepsia and myalgia [38,41]. Riociguat, a
soluble guanylate cyclase stimulator, was evaluated in a phase III clinical
trial and showed promising results [44]. Furthermore, fasudil [45,46]
and dichloroacetate [47], a Rho kinase inhibitor and a pyruvate dehy-
drogenase kinase inhibitor, respectively, include drugs in development
to the treatment of PAH. Dichloroacetate is in evaluation in a phase I
clinical trial (ClinicalTrials.gov Identiﬁer: NCT01083524) (see Table 1).
3. Smooth muscle cells
3.1. Role in pathophysiology of PAH
Vascular SMCs can present different phenotypes, depending on their
functions. These phenotypes are characterized by differences in cellmorphology, proliferation and migration rates and in the expression of
protein markers [48,49]. The different phenotypes are seen in SMCs of
different vessels as well as among SMCs within the same vessel [48]. A
contractile SMC phenotype is typiﬁed by elongated cells, with a slow
growth and migratory rates. On the contrary, synthetic SMCs have a
rhomboid morphology and higher growth and migratory activities
[50]. Once the proteinmarkers used to identify SMCs are also expressed
in other cell types in normal and pathologic situations, the recognition
of these cells is sometimes a difﬁcult task. Currently, the two protein
markersmost used to characterize amature contractile SMC phenotype
are smooth muscle-myosin heavy chain (SM-MHC) and smoothelin.
SM-MHC expression has never been detected in non-SMCs in vivo.
Smoothelin complements SM-MHC as a contractile SMCmarker and ap-
pears to be more sensitive [10,48]. Other markers expressed in a con-
tractile SMC include α-smooth muscle actin (α-SMA), desmin, smooth
muscle-calponin and h-caldesmon. Synthetic SMCs express proteins
like cellular retinol binding protein-1 and SMemb/non-muscle MHC
isoform-B [48,51]. During vascular injury, SMCs “switch” from a con-
tractile to a synthetic, proliferative phenotype to support vascular re-
pair. Importantly, this phenotypic switch is often reversible. However,
deregulation of this process can contribute to the vascular remodeling
associated to PAH [52,53]. Discovering the mechanisms involved in
the SMC phenotype modulation can help to control this “switch” pro-
cess. Examples include pathways/mediators such as TGF-β, PDGF
(platelet-derived growth factor), angiotensin II and TNF (tumor necro-
sis factor)-α [48]. PDGF-A and PDGF-B induce, in adult SMCs, a more
synthetic phenotype [48]. Increased proliferation and migration of
SMCs were observed in pig coronary arteries treated with PDGF-B
[54]. In addition, PDGF-A and PDGF-B inhibition resulted in reduced
SMC proliferation and migration in injured human artery [55,56]. Fur-
thermore, TGF-β isoforms induce a contractile SMC phenotype [48]. Im-
portantly, a recent study investigated the crosstalk between ECs and
SMCs during low shear stress induced vascular remodeling and identi-
ﬁed the factors TGF-β1 and PDGF-BB as important players in this
process. The authors used an EC/SMC cocultured parallel-plate ﬂow
chamber system and each cell type was grown on the opposite sides
of a porousmembrane. Then shear stress was applied to ECs and the ef-
fects were observed. They reported that low shear stress induces the
production of PDGF-BB and TGF-β1 by ECs and the proliferation andmi-
gration of ECs and SMCs. PDGF-BBwas involved in the paracrine control
of SMCs by ECs, and TGF-β1 participates in the feedback control from
SMCs to ECs [57]. More recently, microRNAs (miRNAs) emerged as im-
portant modulators of SMC phenotype, and consequently as possible
therapeutic targets in PAH-related vascular remodeling. These tissue
and cell speciﬁc non-coding single-strand RNA molecules with approx-
imately 19–25 nucleotides negatively regulate gene expression by base
pairing to the 3′-untranslated region of mRNAs, avoiding their transla-
tion [58–60]. SeveralmiRNAs seem to be differentially expressed during
PAH development in the hypoxia andMCT-induced PAH and also in pa-
tients [61,62]. MiR-143, -145 and -204 are examples of miRNAs report-
ed to be involved in SMC phenotype regulation. MiR-204 levels were
found down-regulated in MCT and hypoxic PAH animal models [62].
In addition, in PASMCs from idiopathic PAH patients, miR-204 expres-
sion was also found to be reduced and increased levels of proliferation
and lower levels of apoptosis were veriﬁed in comparison with control
PASMCs. A synthetic miR-204 already showed its beneﬁcial effects in
the pulmonary arteries of MCT rats [61]. The expression of miR-143/
145 was reported to be elevated in hypoxic PAH model and also in pa-
tients with heritable or idiopathic PAH. The increased expression of
miR-143/145 was found to be related with PAH associated with
BMPRII mutation, and so with BMP receptor function loss [63]. Impor-
tantly, BMP signaling pathway is known to inducemiR-143/145 expres-
sion, and so these observations can be explained by the compensatory
increase in TGF-β signaling pathway in response to the decrease in
BMP signaling pathway, once TGF-β mediators also induce miR-143/
145 expression [64].
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Potassium (K+) and calcium (Ca2+) ions have been reported to play
pivotal roles in both vasoconstriction and vascular remodeling in PAH
[65]. When K+ channels are blocked (or K+ channels are down-
regulated), PASMC membrane depolarizes and opens voltage-
dependent Ca2+ channels (VDCC), promoting a Ca2+ inﬂux, increasing
[Ca2+]cyt and causing PASMC vasoconstriction. Conversely, when K+
channels are activated (or K+ channel gene expression is up-
regulated), the membrane hyperpolarizes and closes VDCC, inhibiting
Ca2+ inﬂux, decreasing [Ca2+]cyt and causing vasodilatation [65–67].
Calcium is also an important secondmessenger that leads to cell prolif-
eration and migration through the activation of transcription factors. In
apoptosis, K+ channels mediate the K+ efﬂux that is necessary for apo-
ptotic volume decrease (AVD). K+ efﬂux also leads to the decrease of
[K+]cyt, releasing the inhibition of caspases [65,67]. A defect in gene ex-
pression with attenuated function of Kv channels was reported in
PASMCs from patients with pulmonary hypertension [68]. Thus, a de-
crease in K+ channels gene expression and/or function stimulates
PASMC proliferation by increasing [Ca2+]cyt and inhibits PASMC apo-
ptosis by deceleratingAVD and attenuating cytoplasmic caspase activity
[68]. Although numerous studies have investigated ion channels in PAH,
little is known about the association between the two-pore domain K+
channel, TASK-1, and human PASMCs. Tang et al. [69] reported the in-
volvement of TASK-1 in the ET-1-mediated depolarization in human
PASMCs. The authors concluded that ET-1 depolarizes primary human
PASMCs by phosphorylating (inhibiting) TASK-1 by a mechanism in
which ET-1 binds to the ETA receptor, leading to the protein kinase
C-induced phosphorylation of TASK-1 channels through phospholipase
C, phosphatidylinositol 4, 5-biphosphate and diacylglycerol.
Unfortunately, only 10–15% of idiopathic PAH patients could beneﬁt
from long-term therapy with calcium channel blockers (CCBs) (nifedi-
pine, diltiazem and amlodipine) [70,71]. During diagnosis by cardiac
catheterization, patients perform an acute vasodilator test with agents
such as nitric oxide, prostacyclin or adenosine. If the response to this
test is positive (decrease of at least 10 mm Hg in the mean pulmonary
arterial pressure, to a value of less than 40 mm Hg with an increased
or unchanged cardiac output), the patient can beneﬁt from CCB therapy
[72,73].
4. Fibroblasts
4.1. Role in pathophysiology of PAH
Adventitia, the principal “injury-sensing tissue” of the vessel wall,
undergoes several changes during PAH. Adventitia ﬁbroblasts are able
to proliferate with greater propensity than SMCs in response to injury,
increasing extracellular matrix (ECM) component deposition, and
synthesizing and releasing molecules that act on SMCs and ECs, and fa-
cilitate the recruitment of circulating leucocytes and progenitor cells.
Thus, ﬁbroblasts seem to contribute to inﬂammation and vascular re-
modeling linked to PAH [74,75].
4.2. Intracellular pathways modulated by PAH
The identiﬁcation of ﬁbroblasts is a tricky task, because of the lack of
speciﬁcity and sensitivity of the markers used (vimentin and α-SMA).
Vimentin does not distinguish ﬁbroblasts from other cells of mesenchy-
mal origin and α-SMA is only generally observed in activated ﬁbro-
blasts. In addition, this last marker is observed in SMCs and in
circulating smooth muscle precursors [75]. Activation of ﬁbroblasts re-
sults in their differentiation into myoﬁbroblasts, leading to the produc-
tion of ECM proteins, such as collagen, ﬁbronectin, tenascin and elastin.
The appearance of myoﬁbroblasts expressing α-SMA was observed in
the adventitia in hypoxia-induced PAH [75]. In addition, an excessive
deposition of ECM proteins in the adventitia in PAH was shown [76].Glycosaminoglycans, like hyaluronic acid (HA), are components
of the ECM that control SMC proliferation and differentiation. A
study performedwith idiopathic PAH human lung tissue, showed an in-
crease in the expression of HA associated with increased hyaluronan
synthase-1 (responsible for the synthesis of HA) and decreased
hyaluronoglucosaminidase-1 (important in the degradation of HA)
gene expression [77]. Aytekin et al. [78] veriﬁed that patients with idio-
pathic PAH have higher circulating levels of HA. They also showed that
the expressions of HA synthase-2 and hyaluronidase-2 decrease in idio-
pathic PAH compared with controls. Thus, the decreased HA degrada-
tion seems to have a higher impact than the increased HA production
in the elevated HA levels in PAH. It is known that HA has a variety of bi-
ological functions, which differ according to the molecular weight. HA
degradation in high molecular mass (HMM) fragments (20.000–
500 kDa) manifests immunosuppressant and anti-angiogenic activities.
Conversely, low molecular mass (LMM) HA fragments ( lower than
500 kDa) have been shown to stimulate inﬂammation and to promote
EC and SMC proliferation and migration [79]. Once the accumulation
of pro-inﬂammatory and pro-proliferative HA fragments resulting
frommatrix degradation can be associatedwith PAH-related inﬂamma-
tion and vascular remodeling, Ormiston et al. [80] studied the potential
role of HA degradation at different stages of PAH progression in MCT-
induced PAH. The authors found a generation of LMM HA at the early
stages and an enhanced synthesis of HMM HA in advanced disease.
Thus, the early generation of LMMHA fragments can lead to the inﬂam-
matory and proliferative modulation associated with PAH.
Matrix metalloproteinases (MMPs), a family of zinc enzymes pro-
duced by ﬁbroblasts and macrophages and responsible for degradation
of the ECM components, are also important to SMC and EC migration
and proliferation. Excessive expression of MMPs may contribute to the
pathogenesis of PAH, because MMPs may lead to ﬁbroblast migration
into the media and intima [75]. MMP activity was found to be up-
regulated in adventitial ﬁbroblasts in hypoxia and MCT-induced PAH
[75,81]. Furthermore, also serine elastases can induce the release of
growth factors from the ECM, promoting PASMC proliferation. Elastase
activity was reported to be increased in PAH and serine elastase inhibi-
tors already showed its beneﬁcial effects in hypoxia and MCT-induced
PAH [82–85].
5. Inﬂammatory cells
5.1. Role in pathophysiology of PAH
Inﬂammatory processes have been recognized as major pathogenic
components of pulmonary vascular remodeling [86]. There are several
observations demonstrating that inﬂammation performs a role in PAH
development: i) association of inﬂammatory conditions such as connec-
tive tissue disorders and certain infections like human immunodeﬁcien-
cy viruswith PAH; ii) accumulation of T cells, B cells andmacrophages in
plexiform lesions; iii) detection of auto-antibodies to ECs and ﬁbro-
blasts, and iv) elevation in the circulating levels of certain cytokines
and chemokines [1,11,87]. In addition, a study described an experimen-
tal model of antigen-induced pulmonary arterial muscularization, dem-
onstrating that CD4+ T cells, the IL-4-induced Th2 response, and
endogenous IL-13 can be related with the vascular remodeling process
[88].
5.2. Intracellular pathways modulated by PAH
Mast cells are implicated in inﬂammation and tissue remodeling.
When activated, they produce several mediators including serotonin
(5-HT), cytokines IL-6 and IL-13 and serine proteases chymase and
tryptase that are capable to activate MMPs [89]. It was reported that
mast cells are a rich source of IL-4, aswell as other factors that can stim-
ulate B-cells to secrete auto-antibodies, including anti-endothelial cell
antibodies and its degranulation had been linked to the development
Fig. 2. Interplay between endothelial, smooth muscle and inﬂammatory cells, platelets and
ﬁbroblasts in pulmonary arterial hypertension.Green arrowsdenote the interactionbetween
endothelial cells, platelets and smoothmuscle cells,mediated byNO and PGI2,which leads to
vasodilator, anti-proliferative and anti-platelet aggregation effects. Red arrows show the
interactions mediated by several mediators associated with vasoconstriction, proliferation,
migration and platelet aggregation. Figure made with Servier Medical Art.
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tion, a study demonstrated that the accumulation and activation (de-
granulation) of mast cells in the lungs contribute to the development
of PAH inMCT-rats andmast cell populationwas increased in idiopathic
PAH patients compared with controls [91]. Also, Farha et al. [92] report-
ed that mast cells may promote vascular remodeling, contributing to
PAH in patients. In addition to mast cells, several other inﬂammatory
cells like T cells, B cells and dendritic cells showed to have a role in
PAH development [11,93]. Increased levels of certain cytokines, includ-
ing IL-1β, IL-6 and TNF-α were observed in plasma of PAH patients
[11,86,94]. Importantly, Hagen et al. [95] reported a negative feedback
loop between IL-6 and the BMP pathway, mediated through p38
MAPK activity. Given the low penetrance of BMPRII mutations, alter-
ations in other pathways may be needed to initiate PAH development
and thus, the IL-6 activation can be considered an inﬂammatory “second
hit” associated with the loss of BMP signaling that predisposes to PAH.
With the involvement of inﬂammation in PAH development, several
anti-inﬂammatory and immunosuppressant therapies have emerged.
Examples include rapamycin [96], tryptolide [97] and thymulin [98]
that showed beneﬁcial effects in PAH experimental models.
6. Platelets
6.1. Role in pathophysiology of PAH
Platelet dysfunction is a crucial contributor to PAH-related thrombo-
sis [74]. In addition, also coagulation cascade abnormalities and endo-
thelial cells seem to have a role on it. Underlying these alterations are
increased levels of vonWillebrand factor, plasma ﬁbrinopeptide A, plas-
minogen activator inhibitor (PAI)-1, 5-HT and TXA2, and decreased
levels of tissue plasminogen activator (t-PA), thrombomodulin, NO,
and PGI2 [99,100]. Furthermore, a study recently evaluated, in PAH pa-
tients, the expression of PAR-1 (protease activator receptor-1), an im-
portant mediator of platelet activation by thrombin [101]. The authors
found that the subpopulation of PAH patients that presented lower
platelet counts seems to have increased platelet membrane expression
of PAR-1 and PAR-mediated surface exposure of P-selectin (an adhesion
molecule involved in inﬂammation and thrombosis), whichmay repre-
sent increased propensity to thrombosis.
6.2. Intracellular pathways modulated by PAH
Platelets have secretory granules which contain stored proteins and
small molecules that are released in a regulated manner upon stimula-
tion [102]. Dense granules store molecules such as ATP, ADP, 5-HT,
glutamate, calcium and pyrophosphate. Alpha granules contain an ex-
tensive list of proteins, such as platelet-factor 4 (PF4/CXCL4), RANTES
(CCL5), IL-1α and IL-1β, TGF-β and TNF-α [102]. Thus, platelet activa-
tion in PAH not only promotes thrombosis but also leads to the release
of granule content, including mitogenic agents and vasoconstrictive
substances, such as serotonin [103].
The beneﬁcial effects of several drugs targeting the mechanisms as-
sociated with thrombosis support the important role of this process in
PAH development. Examples of these drugs include thromboxane syn-
thesis inhibitors, such as ozagrel and furegrelate. The ﬁrst showed pos-
itive effects in a patient with portopulmonary hypertension and the
second was tested in a hypoxia PAH experimental model [104,105].
7. Interplay between cell types involved in PAH pathogenesis
Although themechanisms that lead to pulmonary arterial hyperten-
sion are still poorly understood, it is known that the interaction be-
tween vascular cells, inﬂammatory cells and platelets is involved in
the structural changes that culminate in an increased pulmonary arteri-
al pressure. This interplay is regulated by several mediators, which are
highlighted in Fig. 2.The vascular remodeling, mainly characterized by an excessive cell
proliferation and a reduced apoptosis, is one of the most important fea-
tures of PAH. For this structural change, ECs contribute with a pivotal
role, producing and releasing mediators such as NO, PGI2, ET-1 and
TXA2 that control platelet and SMC behavior. In addition to changes in
the production levels of these mediators, also the increased endothelial
barrier permeability counts to the PAH vascular alterations, by exposing
the neighboring cells to these mediators [20,106].
Nitric oxide is synthesized in the endothelial cells from L-arginine by
eNOS. Upon its release by endothelium, NO diffuses into vascular SMCs
where it stimulates soluble guanylate cyclase (sGC) to produce the sec-
ond messenger cyclic guanosine monophosphate (cGMP) from guano-
sine triphosphate (GTP), which has vasodilatory, anti-proliferative and
anti-platelet aggregation properties [2]. The NO pathway is impaired
in several ways in PAH. eNOS expression is depressed [107] and phos-
phodiesterase type 5 is increased in PASMCs,which leads to inactivation
of cGMP [108]. The production of endogenous NOS inhibitors, asym-
metrical and symmetrical dimethylarginines (ADMA and SDMA, re-
spectively), is enhanced in PAH [109]. In addition, sGC expression is
up-regulated in human PAH, as a compensatory mechanism [110]. In
addition to eNOS, also iNOS (inducible NOS) seems to have a role in
PAH, once a recent study reported that iNOS inhibition protected
against PAH [111].
Prostaglandin, generated from arachidonic acid by fatty acid cyclo-
oxygenase, is a substrate for both prostacyclin synthase and thrombox-
ane synthase. Prostacyclin synthase generates PGI2 in PAECs, which
relaxes and inhibits the proliferation of vascular SMCs, and also inhibits
platelet aggregation, via the stimulation of cAMP production [2]. Analy-
sis of urinary metabolites of PGI2 showed a decrease in the amount of
excreted 6-ketoprostaglandin F1α, a prostacyclin inactive metabolite,
in patients with idiopathic PAH [112]. Moreover, PAECs of PAH patients
are characterized by reduced expression of prostacyclin synthase [113].
Prostacyclin receptor expression is also reduced in PASMCs [114].
Thromboxane synthase generates TXA2, which stimulates SMC vaso-
constriction and proliferation and platelet aggregation via thromboxane
receptors [2]. An increase in the urinary excretion of 11-dehydro-
thromboxane B2 (a stable metabolite of thromboxane A2) [112] and in
total body synthesis of TXA2 in patients with idiopathic PAH was veri-
ﬁed [115].
Endothelin-1 is mainly produced by ECs and acts via two receptors:
ETA and ETB. Both receptors are found in PASMCs andmediate vasocon-
striction and proliferation, whereas only the ETB receptor is present in
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[116,117]. Lung and circulating ET-1 levels are increased in PAHpatients
[118]. Another mediator responsible for cell proliferation is PDGF, syn-
thesized and released by several cell types (SMCs, ECs, macrophages
and platelets). The expression of PDGF and its receptors was reported
to be increased in the pulmonary arteries of PAH patients [119], contrib-
uting to a higher proliferation rate of SMCs and ﬁbroblasts. Platelets also
contribute to vascular remodeling through the release of factors such as
PDGF, TXA2 and 5-HT that act on ﬁbroblasts and SMCs leading to
vasoconstriction, proliferation and migration. Cellular migration is also
reported in PAH and is associated with vascular wall thickness.
Myoﬁbroblasts are able to migrate from the adventitia to the media
and to the intima, thus contributing to the thickening of these compo-
nents. For this cell migration MMPs secreted by ﬁbroblasts and macro-
phages might also contribute by degrading ECM components [75,120].
Thrombosis in small peripheral pulmonary arteries also contributes
to PAH. In addition to platelets, ECs are directly involved in this process.
Endothelial cells participate in the coagulation process by activating the
factor X and the extrinsic pathway of coagulation via release of tissue fac-
tor. ECs also produce and release vonWillebrand factor that attracts and
activates platelets [121]. On the other hand, ECs can also inhibit thrombo-
sis and promote ﬁbrinolysis. They produce and release NO and PGI2, two
important inhibitors of platelet aggregation, preventing thrombosis. En-
dothelial cells participate in theﬁbrinolytic process through the synthesis
and release of the proﬁbrinolytic t-PA that activates plasminogen in the
ﬁbrinolytic cascade. In addition, ECs also produce the antiﬁbrinolytic/
prothrombotic PAI-1 [121]. Thus, ECs are important regulators of the bal-
ance between prothrombotic and antithrombotic processes.
PAH-related vasoconstriction also results from the interplay be-
tween several cells, including ECs, SMCs and platelets. Endothelial
cells produce and release vasoconstriction mediators such as ET-1 and
TXA2 that act in SMCs and platelets [2]. On the other hand, platelets re-
lease 5-HT and TXA2 that can act on SMCs and ﬁbroblasts [121]. Seroto-
nin is produced by the gastrointestinal tract enterochromafﬁn cells and
pulmonary neuroepithelial bodies and stored in platelets [122]. It is
taken up by the serotonin transporter (5-HTT or SERT) and the seroto-
nin receptors (5-HT1B, 5-HT2A and 5-HT2B) in the pulmonary artery
smoothmuscle, endothelial cells and ﬁbroblasts [123]. Serotonin is a va-
soconstrictor that stimulates the proliferation of SMCs and ﬁbroblasts
[123,124]. A signiﬁcant rise of 5-HT in plasma is observed in pulmonary
hypertensive patients and the level in platelets is low [125].
In response to inﬂammatory/injury events, vascular cells (ECs and
SMCs) can producemediators such as cytokines and chemokines (solu-
ble cytokines with chemoattractant function) that will be responsible
for the recruitment of inﬂammatory cells (T cells, B cells, macrophages,
dendritic cells,mast cells). These inﬂammatory cells can thereby contin-
ue the release of chemokines, cytokines and also growth factors, such as
VEGF (vascular endothelial growth factor), which will promote EC pro-
liferation and migration and resistance to apoptosis, contributing to the
vascular remodeling [11]. Endothelial cells and SMCs are reported to re-
lease the chemokine CCL2/MCP-1 (monocyte chemotactic protein-1).
The same study showed an increase in CCL2 levels in plasma and lung
tissue of idiopathic PAH patients. In addition, it also showed that mono-
cyte migration was higher in the presence of ECs from PAH patients in
comparison with controls. Furthermore, ECs from PAH patients also
seem to be responsible for the production and release of RANTES (Reg-
ulated upon Activation, Normal T cell Expressed and Secreted)/CCL5 in
PAH patients. An increased expression of RANTES mRNA was observed
in lung tissue from PAH patients [126]. Pulmonary artery ECs from
PAH patients also expressed the chemokine FKN (fractalkine/CX3CL1).
Elevated FKN plasma levels and an increase in FKN mRNA expression
in lung tissue were observed in PAH patients, in comparison with con-
trols. In addition, the FKN receptor (CX3CR1) expression was found to
be increased in vascular SMCs and in circulating T-cells from PAH pa-
tients. Fractalkine was found to induce proliferation but not migration
of cultured rat PASMCs [127,128].8. Conclusions
Despite the success of PAH stabilization with the current medical
therapy targeting pulmonary vascular tone, this disease remains associ-
ated to a poor prognosis. Furthermore, most of the alternative/novel
therapeutic approaches have been studied in experimental models,
and once there is no ideal animal model, the translation of data to
humans is challenging. Therefore, we are still tracking the best treat-
ment for PAH. Considering that disease progression is driven by a cellu-
lar interplay at the pulmonary arterywall that leads to vasoconstriction,
thrombosis, inﬂammation and vascular remodeling, we believe that an
effective treatment must target PAH-related cellular features.Acknowledgements
This work was supported by Fundação para a Ciência e a Tecnologia
(FCT, Portugal), European Union, QREN, FEDER and COMPETE for
funding the Organic Chemistry Research Unit (QOPNA) (project PEst-
C/QUI/UI0062/2013; FCOMP-01-0124-FEDER-037296), the Cardiovas-
cular R&D Unit (project PEst-C/SAU/UI0051/2011) and the post-
graduation student (grant number SFRH/BD/91067/2012).References
[1] S.L. Archer, E.K. Weir, M.R. Wilkins, Basic science of pulmonary arterial hyperten-
sion for clinicians: new concepts and experimental therapies, Circulation 121
(2010) 2045–2066.
[2] M.R. Wilkins, Pulmonary hypertension: the science behind the disease spectrum,
Eur. Respir. Rev. 21 (2012) 19–26.
[3] P. Yildiz, Molecular mechanisms of pulmonary hypertension, Clin. Chim. Acta 403
(2009) 9–16.
[4] G. Simonneau, I.M. Robbins, M. Beghetti, R.N. Channick, M. Delcroix, C.P. Denton,
C.G. Elliott, S.P. Gaine, M.T. Gladwin, Z.C. Jing, M.J. Krowka, D. Langleben, N.
Nakanishi, R. Souza, Updated clinical classiﬁcation of pulmonary hypertension,
J. Am. Coll. Cardiol. 54 (2009) S43–S54.
[5] R.T. Schermuly, H.A. Ghofrani, M.R. Wilkins, F. Grimminger, Mechanisms of dis-
ease: pulmonary arterial hypertension, Nat. Rev. Cardiol. 8 (2011) 443–455.
[6] N. Galiè, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H.
Olschewski, A. Peacock, G. Pietra, L.J. Rubin, G. Simonneau, Guidelines on diagnosis
and treatment of pulmonary arterial hypertension, Eur. Heart J. 25 (2004)
2243–2278.
[7] J.P. Ward, Oxygen sensors in context, Biochim. Biophys. Acta 1777 (2008) 1–14.
[8] P. Fraisl, M. Mazzone, T. Schmidt, P. Carmeliet, Regulation of angiogenesis by oxy-
gen and metabolism, Dev. Cell 16 (2009) 167–179.
[9] J.H. Haga, Y.S. Li, S. Chien, Molecular basis of the effects of mechanical stretch on
vascular smooth muscle cells, J. Biomech. 40 (2007) 947–960.
[10] T. Stevens, S. Phan, M.G. Frid, D. Alvarez, E. Herzog, K.R. Stenmark, Lung vascular
cell heterogeneity: endothelium, smooth muscle, and ﬁbroblasts, Proc. Am. Thorac.
Soc. 5 (2008) 783–791.
[11] S.S. Pullamsetti, R. Savai, W. Janssen, B.K. Dahal, W. Seeger, F. Grimminger, H.A.
Ghofrani, N. Weissmann, R.T. Schermuly, Inﬂammation, immunological reaction
and role of infection in pulmonary hypertension, Clin. Microbiol. Infect. 17 (2011)
7–14.
[12] S. Sakao, K. Tatsumi, N.F. Voelkel, Endothelial cells and pulmonary arterial hyper-
tension: apoptosis, proliferation, interaction and transdifferentiation, Respir. Res.
10 (2009) 95.
[13] C. Urbich, S. Dimmeler, Endothelial progenitor cells, Circ. Res. 95 (2004) 343–353.
[14] G.-P. Diller, T. Thum, M.R. Wilkins, J. Wharton, Endothelial progenitor cells in pul-
monary arterial hypertension, Trends Cardiovasc. Med. 20 (2010) 22–29.
[15] X.-X. Wang, F.-R. Zhang, Y.-P. Shang, J.-H. Zhu, X.-D. Xie, Q.-M. Tao, J.-H. Zhu, J.-Z.
Chen, Transplantation of autologous endothelial progenitor cells may be beneﬁcial
in patients with idiopathic pulmonary arterial hypertension: a pilot randomized
controlled trial, J. Am. Coll. Cardiol. 49 (2007) 1566–1571.
[16] J.H. Zhu, X.X.Wang, F.R. Zhang, Y.P. Shang, Q.M. Tao, J.Z. Chen, Safety and efﬁcacy of
autologous endothelial progenitor cells transplantation in children with idiopathic
pulmonary arterial hypertension: open-label pilot study, Pediatr. Transplant. 12
(2008) 650–655.
[17] M. Toshner, R. Voswinckel, M. Southwood, R. Al-Lamki, L.S. Howard, D. Marchesan,
J. Yang, J. Suntharalingam, E. Soon, A. Exley, S. Stewart, M. Hecker, Z. Zhu, U.
Gehling, W. Seeger, J. Pepke-Zaba, N.W. Morrell, Evidence of dysfunction of endo-
thelial progenitors in pulmonary arterial hypertension, Am. J. Respir. Crit. Care
Med. 180 (2009) 780–787.
[18] C.K. Sun, Y.C. Lin, C.M. Yuen, S. Chua, L.T. Chang, J.J. Sheu, F.Y. Lee, M. Fu, S. Leu, H.K.
Yip, Enhanced protection against pulmonary hypertension with sildenaﬁl and
endothelial progenitor cell in rats, Int. J. Cardiol. 162 (2011) 45–58.
[19] M.L. Ormiston, Y. Deng, D.J. Stewart, D.W. Courtman, Innate immunity in the ther-
apeutic actions of endothelial progenitor cells in pulmonary hypertension, Am. J.
Respir. Cell Mol. Biol. 43 (2010) 546–554.
891R. Nogueira-Ferreira et al. / Biochimica et Biophysica Acta 1843 (2014) 885–893[20] N.W. Morrell, S. Adnot, S.L. Archer, J. Dupuis, P. Lloyd Jones, M.R. MacLean, I.F.
McMurtry, K.R. Stenmark, P.A. Thistlethwaite, N. Weissmann, J.X.J. Yuan, E.K.
Weir, Cellular and molecular basis of pulmonary arterial hypertension, J. Am.
Coll. Cardiol. 54 (2009) S20–S31.
[21] C. Csortos, I. Kolosova, A.D. Verin, Regulation of vascular endothelial cell barrier
function and cytoskeleton structure by protein phosphatases of the PPP family,
Am. J. Physiol. Lung Cell. Mol. Physiol. 293 (2007) L843–L854.
[22] V.J. Burton, L.I. Ciuclan, A.M. Holmes, D.M. Rodman, C. Walker, D.C. Budd, Bone
morphogenetic protein receptor II regulates pulmonary artery endothelial cell
barrier function, Blood 117 (2011) 333–341.
[23] J.W. Lowery, M.P. de Caestecker, BMP signaling in vascular development and
disease, Cytokine Growth Factor Rev. 21 (2010) 287–298.
[24] J. Cai, E. Pardali, G. Sanchez-Duffhues, P. ten Dijke, BMP signaling in vascular
diseases, FEBS Lett. 586 (2012) 1993–2002.
[25] R.J.Davies, N.W.Morrell,Molecularmechanisms of pulmonary arterial hypertension:
role of mutations in the bone morphogenetic protein type II receptor, Chest 134
(2008) 1271–1277.
[26] R.D. Machado, M.A. Aldred, V. James, R.E. Harrison, B. Patel, E.C. Schwalbe, E.
Gruenig, B. Janssen, R. Koehler, W. Seeger, O. Eickelberg, H. Olschewski, C.
Gregory Elliott, E. Glissmeyer, J. Carlquist, M. Kim, A. Torbicki, A. Fijalkowska, G.
Szewczyk, J. Parma, M.J. Abramowicz, N. Galie, H. Morisaki, S. Kyotani, N.
Nakanishi, T. Morisaki, M. Humbert, G. Simonneau, O. Sitbon, F. Soubrier, F.
Coulet, N.W. Morrell, R.C. Trembath, Mutations of the TGF-β type II receptor
BMPR2 in pulmonary arterial hypertension, Hum. Mutat. 27 (2006) 121–132.
[27] C. Atkinson, S. Stewart, P.D. Upton, R. Machado, J.R. Thomson, R.C. Trembath, N.W.
Morrell, Primary pulmonary hypertension is associated with reduced pulmonary
vascular expression of type II bone morphogenetic protein receptor, Circulation
105 (2002) 1672–1678.
[28] K. Teichert-Kuliszewska, M.J.B. Kutryk, M.A. Kuliszewski, G. Karoubi, D.W.
Courtman, L. Zucco, J. Granton, D.J. Stewart, Bone morphogenetic protein
receptor-2 signaling promotes pulmonary arterial endothelial cell survival, Circ.
Res. 98 (2006) 209–217.
[29] G. Valdimarsdottir, M.-J. Goumans, A. Rosendahl, M. Brugman, S. Itoh, F. Lebrin, P.
Sideras, P. ten Dijke, Stimulation of Id1 expression by bone morphogenetic protein
is sufﬁcient and necessary for bone morphogenetic protein-induced activation of
endothelial cells, Circulation 106 (2002) 2263–2270.
[30] A. Gangopahyay, M. Oran, E.M. Bauer, J.W. Wertz, S.A. Comhair, S.C. Erzurum, P.M.
Bauer, Bone morphogenetic protein receptor II is a novel mediator of endothelial
nitric-oxide synthase activation, J. Biol. Chem. 286 (2011) 33134–33140.
[31] W. Xu, T. Koeck, A.R. Lara, D. Neumann, F.P. DiFilippo, M. Koo, A.J. Janocha, F.A.
Masri, A.C. Arroliga, C. Jennings, R.A. Dweik, R.M. Tuder, D.J. Stuehr, S.C. Erzurum,
Alterations of cellular bioenergetics in pulmonary artery endothelial cells, Proc.
Natl. Acad. Sci. U. S. A. 104 (2007) 1342–1347.
[32] P.B. Sehgal, J.E. Lee, Protein trafﬁcking dysfunctions: role in the pathogenesis of
pulmonary arterial hypertension, Pulm. Circ. 1 (2011) 17–32.
[33] P.B. Sehgal, S. Mukhopadhyay, Pulmonary arterial hypertension: a disease of
tethers, SNAREs and SNAPs? Am. J. Physiol. Heart Circ. Physiol. 293 (2007)
H77–H85.
[34] J.S. Bonifacino, B.S. Glick, The mechanisms of vesicle budding and fusion, Cell 116
(2004) 153–166.
[35] R. Mathew, J. Huang, M. Shah, K. Patel, M. Gewitz, P.B. Sehgal, Disruption
of endothelial-cell caveolin-1α/raft scaffolding during development of
monocrotaline-induced pulmonary hypertension, Circulation 110 (2004)
1499–1506.
[36] S. Mukhopadhyay, F. Xu, P.B. Sehgal, Aberrant cytoplasmic sequestration of eNOS
in endothelial cells aftermonocrotaline, hypoxia, and senescence: live-cell caveolar
and cytoplasmic NO imaging, Am. J. Physiol. Heart Circ. Physiol. 292 (2007)
H1373–H1389.
[37] P.B. Sehgal, S. Mukhopadhyay, F. Xu, K. Patel, M. Shah, Dysfunction of Golgi tethers,
SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension, Am. J.
Physiol. Lung Cell. Mol. Physiol. 292 (2007) L1526–L1542.
[38] D. Montani, M.C. Chaumais, C. Guignabert, S. Gunther, B. Girerd, X. Jais, V.
Algalarrondo, L.C. Price, L. Savale, O. Sitbon, G. Simonneau, M. Humbert, Targeted
therapies in pulmonary arterial hypertension, Pharmacol. Ther. 141 (2014) 172–191.
[39] A. Fuentes, A. Coralic, K.L. Dawson, A new epoprostenol formulation for the treat-
ment of pulmonary arterial hypertension, Am. J. Health Syst. Pharm. 69 (2012)
1389–1393.
[40] O. Lambert, D. Bandilla, Stability and preservation of a new formulation of
epoprostenol sodium for treatment of pulmonary arterial hypertension, Drug
Des. Devel. Ther. 6 (2012) 235–244.
[41] A. Seferian, G. Simonneau, Therapies for pulmonary arterial hypertension: where
are we today, where do we go tomorrow? Eur. Respir. Rev. 22 (2013) 217–226.
[42] Y. Wu, D.S. O'Callaghan, M. Humbert, An update on medical therapy for pulmonary
arterial hypertension, Curr. Hypertens. Rep. 15 (2013) 614–622.
[43] T. Pulido, I. Adzerikho, R.N. Channick, M. Delcroix, N. Galiè, H.-A. Ghofrani, P. Jansa,
Z.-C. Jing, F.-O. Le Brun, S. Mehta, C.M. Mittelholzer, L. Perchenet, B.K.S. Sastry, O.
Sitbon, R. Souza, A. Torbicki, X. Zeng, L.J. Rubin, G. Simonneau, Macitentan and
morbidity and mortality in pulmonary arterial hypertension, N. Engl. J. Med. 369
(2013) 809–818.
[44] H.-A. Ghofrani, N. Galiè, F. Grimminger, E. Grünig, M. Humbert, Z.-C. Jing, A.M.
Keogh, D. Langleben, M.O. Kilama, A. Fritsch, D. Neuser, L.J. Rubin, Riociguat for
the treatment of pulmonary arterial hypertension, N. Engl. J. Med. 369 (2013)
330–340.
[45] H. Fujita, Y. Fukumoto, K. Saji, K. Sugimura, J. Demachi, J. Nawata, H. Shimokawa,
Acute vasodilator effects of inhaled fasudil, a speciﬁc Rho-kinase inhibitor, in pa-
tients with pulmonary arterial hypertension, Heart Vessels 25 (2010) 144–149.[46] V. Gupta, N. Gupta, I.H. Shaik, R. Mehvar, I.F. McMurtry,M. Oka, E. Nozik-Grayck, M.
Komatsu, F. Ahsan, Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmo-
nary preferential vasodilation in pulmonary arterial hypertension, J. Control.
Release 167 (2013) 189–199.
[47] V.V. McLaughlin, Looking to the future: a new decade of pulmonary arterial hyper-
tension therapy, Eur. Respir. Rev. 20 (2011) 262–269.
[48] S.S. Rensen, P.A. Doevendans, G.J. van Eys, Regulation and characteristics of vascu-
lar smooth muscle cell phenotypic diversity, Neth. Heart J. 15 (2007) 100–108.
[49] K. Kawai-Kowase, G.K. Owens, Multiple repressor pathways contribute to pheno-
typic switching of vascular smooth muscle cells, Am. J. Physiol. Cell Physiol. 292
(2007) C59–C69.
[50] H. Hao, G. Gabbiani, M.-L. Bochaton-Piallat, Arterial smooth muscle cell heteroge-
neity, Arterioscler. Thromb. Vasc. 23 (2003) 1510–1520.
[51] A.J. Halayko, J. Solway, Invited review: molecular mechanisms of phenotypic plas-
ticity in smooth muscle cells, J. Appl. Physiol. 90 (2001) 358–368.
[52] E.M. Rzucidlo, K.A. Martin, R.J. Powell, Regulation of vascular smooth muscle cell
differentiation, J. Vasc. Surg. 45 (2007) A25–A32.
[53] S.J. House, M. Potier, J. Bisaillon, H.A. Singer, M. Trebak, The non-excitable smooth
muscle: calcium signaling and phenotypic switching during vascular disease,
Pﬂugers Arch. 456 (2008) 769–785.
[54] H. Hao, P. Ropraz, V. Verin, E. Camenzind, A. Geinoz, M.S. Pepper, G. Gabbiani, M.-L.
Bochaton-Piallat, Heterogeneity of smooth muscle cell populations cultured from
pig coronary artery, Arterioscler. Thromb. Vasc. 22 (2002) 1093–1099.
[55] M. Kotani, N. Fukuda, H. Ando, W.-Y. Hu, S. Kunimoto, S. Saito, K. Kanmatsuse, Chi-
meric DNA–RNA hammerhead ribozyme targeting PDGF A-chainmRNA speciﬁcally
inhibits neointima formation in rat carotid artery after balloon injury, Cardiovasc.
Res. 57 (2003) 265–276.
[56] J. Deguchi, T. Namba, H. Hamada, T. Nakaoka, J. Abe, O. Sato, T. Miyata, M.
Makuuchi, K. Kurokawa, Y. Takuwa, Targeting endogenous platelet-derived
growth factor B-chain by adenovirus-mediated gene transfer potently inhibits
in vivo smooth muscle proliferation after arterial injury, Gene Ther. 6 (1999)
956–965.
[57] Y.X. Qi, J. Jiang, X.H. Jiang, X.D.Wang, S.Y. Ji, Y. Han, D.K. Long, B.R. Shen, Z.Q. Yan, S.
Chien, Z.L. Jiang, PDGF-BB and TGF-{beta}1 on cross-talk between endothelial and
smoothmuscle cells in vascular remodeling induced by low shear stress, Proc. Natl.
Acad. Sci. U. S. A. 108 (2011) 1908–1913.
[58] K. Yuan, M. Orcholski, X. Tian, X. Liao, V.A. de Jesus Perez, MicroRNAs: promising
therapeutic targets for the treatment of pulmonary arterial hypertension, Expert
Opin. Ther. Targets 17 (2013) 557–564.
[59] Y. Wang, X.Y. Xue, Y.X. Liu, K.F. Wang, X.F. Zang, J.Wang, P.L. Wang, J. Zhang, L. Pan,
S.Y. Zhang, J.X. Wang, Pulmonary arterial hypertension and microRNAs—an
ever-growing partnership, Arch. Med. Res. 44 (2013) 483–487.
[60] J.S. Grant, K. White, M.R. Maclean, A.H. Baker, MicroRNAs in pulmonary arterial re-
modeling, Cell. Mol. Life Sci. 70 (2013) 4479–4494.
[61] A. Courboulin, R. Paulin, N.J. Giguere, N. Saksouk, T. Perreault, J. Meloche, E.R.
Paquet, S. Biardel, S. Provencher, J. Cote, M.J. Simard, S. Bonnet, Role for miR-204
in human pulmonary arterial hypertension, J. Exp. Med. 208 (2011) 535–548.
[62] P. Caruso, M.R. MacLean, R. Khanin, J. McClure, E. Soon, M. Southgate, R.A.
MacDonald, J.A. Greig, K.E. Robertson, R. Masson, L. Denby, Y. Dempsie, L. Long,
N.W. Morrell, A.H. Baker, Dynamic changes in lung microRNA proﬁles during the
development of pulmonary hypertension due to chronic hypoxia and monocrota-
line, Arterioscler. Thromb. Vasc. 30 (2010) 716–723.
[63] P. Caruso, Y. Dempsie, H.C. Stevens, R.A. McDonald, L. Long, R. Lu, K. White, K.M.
Mair, J.D. McClure, M. Southwood, P. Upton, M. Xin, E. van Rooij, E.N. Olson, N.W.
Morrell, M.R. MacLean, A.H. Baker, A role for miR-145 in pulmonary arterial
hypertension: evidence from mouse models and patient samples, Circ. Res. 111
(2012) 290–300.
[64] B.N. Davis-Dusenbery, M.C. Chan, K.E. Reno, A.S. Weisman, M.D. Layne, G. Lagna, A.
Hata, Down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is
critical for modulation of vascular smooth muscle cell phenotype by transforming
growth factor-beta and bone morphogenetic protein 4, J. Biol. Chem. 286 (2011)
28097–28110.
[65] E.D. Burg, C.V. Remillard, J.X. Yuan, Potassium channels in the regulation of pulmo-
nary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic
implications, Br. J. Pharmacol. 153 (Suppl. 1) (2008) S99–S111.
[66] R.A. Fernandez, P. Sundivakkam, K.A. Smith, A.S. Zeifman, A.R. Drennan, J.X. Yuan,
Pathogenic role of store-operated and receptor-operated Ca(2+) channels in pul-
monary arterial hypertension, J. Signal Transduct. 2012 (2012) 951497.
[67] F.K. Kuhr, K.A. Smith, M.Y. Song, I. Levitan, J.X. Yuan, New mechanisms of pulmo-
nary arterial hypertension: role of Ca(2)(+) signaling, Am. J. Physiol. Heart Circ.
Physiol. 302 (2012) H1546–H1562.
[68] M. Mandegar, J.X.J. Yuan, Role of K+ channels in pulmonary hypertension, Vasc.
Pharmacol. 38 (2002) 25–33.
[69] B. Tang, Y. Li, C. Nagaraj, R.E. Morty, S. Gabor, E. Stacher, R. Voswinckel, N.
Weissmann, K. Leithner, H. Olschewski, A. Olschewski, Endothelin-1 inhibits back-
ground two-pore domain channel TASK-1 in primary human pulmonary artery
smooth muscle cells, Am. J. Respir. Cell Mol. Biol. 41 (2009) 476–483.
[70] R.S. Baliga, R.J. MacAllister, A.J. Hobbs, New perspectives for the treatment of
pulmonary hypertension, Br. J. Pharmacol. 163 (2011) 125–140.
[71] H. Gupta, G. Ghimire, R. Naeije, The value of tools to assess pulmonary arterial
hypertension, Eur. Respir. Rev. 20 (2011) 222–235.
[72] O. Sitbon, M. Humbert, X. Jais, V. Ioos, A.M. Hamid, S. Provencher, G. Garcia, F.
Parent, P. Herve, G. Simonneau, Long-term response to calcium channel blockers
in idiopathic pulmonary arterial hypertension, Circulation 111 (2005) 3105–3111.
[73] N. Galie, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, J.A. Barbera, M.
Beghetti, P. Corris, S. Gaine, J.S. Gibbs, M.A. Gomez-Sanchez, G. Jondeau, W.
892 R. Nogueira-Ferreira et al. / Biochimica et Biophysica Acta 1843 (2014) 885–893Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger, G. Simonneau, Guidelines for
the diagnosis and treatment of pulmonary hypertension: the Task Force for the
Diagnosis and Treatment of Pulmonary Hypertension of the European Society of
Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the
International Society of Heart and Lung Transplantation (ISHLT), Eur. Heart J. 30
(2009) 2493–2537.
[74] M. Prabha, H.F. Jin, Y. Tian, C.S. Tang, J.B. Du, Mechanisms responsible for pulmo-
nary hypertension, Chin. Med. J. (Engl.) 121 (2008) 2604–2609.
[75] K.R. Stenmark, N. Davie, M. Frid, E. Gerasimovskaya, M. Das, Role of the adventitia
in pulmonary vascular remodeling, Physiology (Bethesda) 21 (2006) 134–145.
[76] A.G. Durmowicz, W.C. Parks, D.M. Hyde, R.P. Mecham, K.R. Stenmark, Persistence,
re-expression, and induction of pulmonary arterial ﬁbronectin, tropoelastin, and
type I procollagenmRNA expression in neonatal hypoxic pulmonary hypertension,
Am. J. Pathol. 145 (1994) 1411–1420.
[77] E. Papakonstantinou, F.M. Kouri, G. Karakiulakis, I. Klagas, O. Eickelberg, Increased
hyaluronic acid content in idiopathic pulmonary arterial hypertension, Eur. Respir.
J. 32 (2008) 1504–1512.
[78] M. Aytekin, S.A.A. Comhair, C. de la Motte, S.K. Bandyopadhyay, C.F. Farver, V.C.
Hascall, S.C. Erzurum, R.A. Dweik, High levels of hyaluronan in idiopathic pulmo-
nary arterial hypertension, Am. J. Physiol. Lung Cell. Mol. Physiol. 295 (2008)
L789–L799.
[79] K.A. Scheibner, M.A. Lutz, S. Boodoo, M.J. Fenton, J.D. Powell, M.R. Horton,
Hyaluronan fragments act as an endogenous danger signal by engaging TLR2,
J. Immunol. 177 (2006) 1272–1281.
[80] M.L. Ormiston, G.R. Slaughter, Y. Deng, D.J. Stewart, D.W. Courtman, The enzymatic
degradation of hyaluronan is associated with disease progression in experimental
pulmonary hypertension, Am. J. Physiol. Lung Cell. Mol. Physiol. 298 (2010)
L148–L157.
[81] E. Frisdal, V. Gest, A. Vieillard-Baron, M. Levame, H. Lepetit, S. Eddahibi, C. Lafuma,
A. Harf, S. Adnot, M.P. Dortho, Gelatinase expression in pulmonary arteries during
experimental pulmonary hypertension, Eur. Respir. J. 18 (2001) 838–845.
[82] L.J. Fu, A.Q. Zhou, J. Shen, W. Zhao, F. Li, Effect of elastase inhibitor on pulmonary
hypertension induced by monocrotaline, Zhonghua Er Ke Za Zhi 42 (2004)
375–378.
[83] M. Rabinovitch, Elastase and the pathobiology of unexplained pulmonary hyper-
tension, Chest 114 (1998) 213S–224S.
[84] K. Thompson, M. Rabinovitch, Exogenous leukocyte and endogenous elastases can
mediate mitogenic activity in pulmonary artery smooth muscle cells by release of
extracellular-matrix bound basic ﬁbroblast growth factor, J. Cell. Physiol. 166
(1996) 495–505.
[85] S.H. Zaidi, X.M. You, S. Ciura, M. Husain, M. Rabinovitch, Overexpression of the ser-
ine elastase inhibitor elaﬁn protects transgenic mice from hypoxic pulmonary hy-
pertension, Circulation 105 (2002) 516–521.
[86] P.M. Hassoun, L. Mouthon, J.A. Barberà, S. Eddahibi, S.C. Flores, F. Grimminger, P.L.
Jones, M.L. Maitland, E.D. Michelakis, N.W. Morrell, J.H. Newman, M. Rabinovitch,
R. Schermuly, K.R. Stenmark, N.F. Voelkel, J.X.J. Yuan, M. Humbert, Inﬂammation,
growth factors, and pulmonary vascular remodeling, J. Am. Coll. Cardiol. 54
(2009) S10–S19.
[87] N.W. Morrell, S.L. Archer, A. Defelice, S. Evans, M. Fiszman, T. Martin, M. Saulnier,
M. Rabinovitch, R. Schermuly, D. Stewart, H. Truebel, G.Walker, K.R. Stenmark, An-
ticipated classes of new medications and molecular targets for pulmonary arterial
hypertension, Pulm. Circ. 3 (2013) 226–244.
[88] E. Daley, C. Emson, C. Guignabert, R. de Waal Malefyt, J. Louten, V.P. Kurup, C.
Hogaboam, L. Taraseviciene-Stewart, N.F. Voelkel, M. Rabinovitch, E. Grunig, G.
Grunig, Pulmonary arterial remodeling induced by a Th2 immune response,
J. Exp. Med. 205 (2008) 361–372.
[89] A.M. Gilﬁllan, J. Rivera, The tyrosine kinase network regulating mast cell activation,
Immunol. Rev. 228 (2009) 149–169.
[90] A. Banasova, H. Maxova, V. Hampl, M. Vizek, V. Povysilova, J. Novotna, O.
Vajnerova, O. Hnilickova, J. Herget, Prevention of mast cell degranulation by
disodium cromoglycate attenuates the development of hypoxic pulmonary hyper-
tension in rats exposed to chronic hypoxia, Respiration 76 (2008) 102–107.
[91] B.K. Dahal, D. Kosanovic, C. Kaulen, T. Cornitescu, R. Savai, J. Hoffmann, I. Reiss, H.A.
Ghofrani, N. Weissmann, W.M. Kuebler, W. Seeger, F. Grimminger, R.T. Schermuly,
Involvement of mast cells in monocrotaline-induced pulmonary hypertension in
rats, Respir. Res. 12 (2011) 60.
[92] S. Farha, J. Sharp, K. Asosingh, M. Park, S.A. Comhair, W.H. Tang, J. Thomas, C.
Farver, F. Hsieh, J.E. Loyd, S.C. Erzurum, Mast cell number, phenotype, and function
in human pulmonary arterial hypertension, Pulm. Circ. 2 (2012) 220–228.
[93] L.C. Price, S.J. Wort, F. Perros, P. Dorfmuller, A. Huertas, D. Montani, S.
Cohen-Kaminsky, M. Humbert, Inﬂammation in pulmonary arterial hypertension,
Chest 141 (2012) 210–221.
[94] N. Selimovic, C.H. Bergh, B. Andersson, E. Sakiniene, H. Carlsten, B. Rundqvist,
Growth factors and interleukin-6 across the lung circulation in pulmonary hyper-
tension, Eur. Respir. J. 34 (2009) 662–668.
[95] M. Hagen, K. Fagan, W. Steudel, M. Carr, K. Lane, D.M. Rodman, J. West, Interaction
of interleukin-6 and the BMP pathway in pulmonary smoothmuscle, Am. J. Physiol.
Lung Cell. Mol. Physiol. 292 (2007) L1473–L1479.
[96] T. Nishimura, J.L. Faul, G.J. Berry, I. Veve, R.G. Pearl, P.N. Kao, 40-O-
(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and
neointimal formation in rats, Am. J. Respir. Crit. Care Med. 163 (2001) 498–502.
[97] J.L. Faul, T. Nishimura, G.J. Berry, G.V. Benson, R.G. Pearl, P.N. Kao, Triptolide atten-
uates pulmonary arterial hypertension and neointimal formation in rats, Am. J.
Respir. Crit. Care Med. 162 (2000) 2252–2258.
[98] T. Henriques-Coelho, S.M. Oliveira, R.S. Moura, R. Roncon-Albuquerque Jr., A.L.
Neves, M. Santos, C. Nogueira-Silva, F. La Fuente Carvalho, A. Brandao-Nogueira,J. Correia-Pinto, A.F. Leite-Moreira, Thymulin inhibits monocrotaline-induced pul-
monary hypertension modulating interleukin-6 expression and suppressing p38
pathway, Endocrinology 149 (2008) 4367–4373.
[99] V.V. McLaughlin, M.D. McGoon, Pulmonary arterial hypertension, Circulation 114
(2006) 1417–1431.
[100] K.S. Zanjani, Platelets in pulmonary hypertension: a causative role or a simple as-
sociation? Iran. J. Pediatr. 22 (2012) 145–157.
[101] N.Y. Maeda, J.H. Carvalho, A.H. Otake, S.M.F. Mesquita, S.P. Bydlowski, A.A. Lopes,
Platelet protease-activated receptor 1 and membrane expression of P-selectin in
pulmonary arterial hypertension, Thromb. Res. 125 (2010) 38–43.
[102] G. Shi, C.N. Morrell, Platelets as initiators andmediators of inﬂammation at the ves-
sel wall, Thromb. Res. 127 (2011) 387–390.
[103] H.W. Farber, J. Loscalzo, Prothrombotic mechanisms in primary pulmonary hyper-
tension, J. Lab. Clin. Med. 134 (1999) 561–566.
[104] S.D. Hirenallur, N.D. Detweiler, S.T. Haworth, J.T. Leming, J.B. Gordon, N.J. Rusch,
Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmo-
nary arterial hypertension in neonatal piglets, Pulm. Circ. 2 (2012) 193–200.
[105] T. Maruyama, K. Ohsaki, S. Shimoda, Y. Kaji, M. Harada, Thromboxane-dependent
portopulmonary hypertension, Am. J. Med. 118 (2005) 93–94.
[106] M. Humbert, D. Montani, F. Perros, P. Dorfmuller, S. Adnot, S. Eddahibi, Endothelial
cell dysfunction and cross talk between endothelium and smooth muscle cells in
pulmonary arterial hypertension, Vasc. Pharmacol. 49 (2008) 113–118.
[107] A. Giaid, D. Saleh, Reduced expression of endothelial nitric oxide synthase in the
lungs of patients with pulmonary hypertension, N. Engl. J. Med. 333 (1995)
214–221.
[108] F. Murray, M.R. MacLean, N.J. Pyne, Increased expression of the cGMP-inhibited
cAMP-speciﬁc (PDE3) and cGMP binding cGMP-speciﬁc (PDE5) phosphodiester-
ases inmodels of pulmonaryhypertension, Br. J. Pharmacol. 137 (2002) 1187–1194.
[109] S. Pullamsetti, L. Kiss, H.A. Ghofrani, R. Voswinckel, P. Haredza, W. Klepetko, C.
Aigner, L. Fink, J.P. Muyal, N. Weissmann, F. Grimminger, W. Seeger, R.T.
Schermuly, Increased levels and reduced catabolism of asymmetric and symmetric
dimethylarginines in pulmonary hypertension, FASEB J. 19 (2005) 1175–1177.
[110] R.T. Schermuly, J.-P. Stasch, S.S. Pullamsetti, R. Middendorff, D. Müller, K.-D.
Schlüter, A. Dingendorf, S. Hackemack, E. Kolosionek, C. Kaulen, R. Dumitrascu,
N. Weissmann, J. Mittendorf, W. Klepetko, W. Seeger, H.A. Ghofrani, F.
Grimminger, Expression and function of soluble guanylate cyclase in pulmonary
arterial hypertension, Eur. Respir. J. 32 (2008) 881–891.
[111] M. Seimetz, N. Parajuli, A. Pichl, F. Veit, G. Kwapiszewska, F.C. Weisel, K. Milger, B.
Egemnazarov, A. Turowska, B. Fuchs, S. Nikam, M. Roth, A. Sydykov, T. Medebach,
W. Klepetko, P. Jaksch, R. Dumitrascu, H. Garn, R. Voswinckel, S. Kostin, W. Seeger,
R.T. Schermuly, F. Grimminger, H.A. Ghofrani, N. Weissmann, Inducible NOS inhibi-
tion reverses tobacco-smoke-induced emphysema and pulmonary hypertension in
mice, Cell 147 (2011) 293–305.
[112] B.W. Christman, C.D. McPherson, J.H. Newman, G.A. King, G.R. Bernard, B.M.
Groves, J.E. Loyd, An imbalance between the excretion of thromboxane and pros-
tacyclin metabolites in pulmonary hypertension, N. Engl. J. Med. 327 (1992)
70–75.
[113] R.M. Tuder, C.D. Cool, M.W. Geraci, J. Wang, S.H. Abman, L. Wright, D. Badesch, N.F.
Voelkel, Prostacyclin synthase expression is decreased in lungs from patients with
severe pulmonary hypertension, Am. J. Respir. Crit. Care Med. 159 (1999)
1925–1932.
[114] Y. Hoshikawa, N.F. Voelkel, T.L. Gesell, M.D. Moore, K.G. Morris, L.A. Alger, S.
Narumiya, M.W. Geraci, Prostacyclin receptor-dependent modulation of pulmo-
nary vascular remodeling, Am. J. Respir. Crit. Care Med. 164 (2001) 314–318.
[115] I.M. Robbins, R.J. Barst, L.J. Rubin, S.P. Gaine, P.V. Price, J.D.Morrow, B.W. Christman,
Increased levels of prostaglandin D2 suggest macrophage activation in patients
with primary pulmonary hypertension, Chest 120 (2001) 1639–1644.
[116] Y. Kawanabe, S.M. Nauli, Endothelin, Cell. Mol. Life Sci. 68 (2011) 195–203.
[117] C.J. Rhodes, A. Davidson, J.S. Gibbs, J. Wharton, M.R. Wilkins, Therapeutic targets in
pulmonary arterial hypertension, Pharmacol. Ther. 121 (2009) 69–88.
[118] A. Giaid, M. Yanagisawa, D. Langleben, R.P. Michel, R. Levy, H. Shennib, S. Kimura, T.
Masaki, W.P. Duguid, D.J. Stewart, Expression of endothelin-1 in the lungs of pa-
tients with pulmonary hypertension, N. Engl. J. Med. 328 (1993) 1732–1739.
[119] F. Perros, D. Montani, P. Dorfmuller, I. Durand-Gasselin, C. Tcherakian, J. Le Pavec,
M. Mazmanian, E. Fadel, S. Mussot, O. Mercier, P. Herve, D. Emilie, S. Eddahibi, G.
Simonneau, R. Souza, M. Humbert, Platelet-derived growth factor expression and
function in idiopathic pulmonary arterial hypertension, Am. J. Respir. Crit. Care
Med. 178 (2008) 81–88.
[120] E.S. Yi, H. Kim, H. Ahn, J. Strother, T. Morris, E. Masliah, L.A. Hansen, K. Park, P.J.
Friedman, Distribution of obstructive intimal lesions and their cellular phenotypes
in chronic pulmonary hypertension. A morphometric and immunohistochemical
study, Am. J. Respir. Crit. Care Med. 162 (2000) 1577–1586.
[121] G. Berger, Z.S. Azzam, R. Hoffman, M. Yigla, Coagulation and anticoagulation in pul-
monary arterial hypertension, Isr. Med. Assoc. J. 11 (2009) 376–379.
[122] M. Humbert, N.W. Morrell, S.L. Archer, K.R. Stenmark, M.R. MacLean, I.M. Lang,
B.W. Christman, E.K. Weir, O. Eickelberg, N.F. Voelkel, M. Rabinovitch, Cellular
and molecular pathobiology of pulmonary arterial hypertension, J. Am. Coll.
Cardiol. 43 (2004) 13S–24S.
[123] E.K. Weir, Z. Hong, A. Varghese, The serotonin transporter: a vehicle to elucidate
pulmonary hypertension? Circ. Res. 94 (2004) 1152–1154.
[124] D.J. Welsh, M. Harnett, M. MacLean, A.J. Peacock, Proliferation and signaling in ﬁ-
broblasts: role of 5-hydroxytryptamine2A receptor and transporter, Am. J. Respir.
Crit. Care Med. 170 (2004) 252–259.
[125] P. Hervé, J.-M. Launay, M.-L. Scrobohaci, F. Brenot, G. Simonneau, P. Petitpretz, P.
Poubeau, J. Cerrina, P. Duroux, L. Drouet, Increased plasma serotonin in primary
pulmonary hypertension, Am. J. Med. 99 (1995) 249–254.
893R. Nogueira-Ferreira et al. / Biochimica et Biophysica Acta 1843 (2014) 885–893[126] P. Dorfmuller, V. Zarka, I. Durand-Gasselin, G. Monti, K. Balabanian, G. Garcia, F.
Capron, A. Coulomb-Lhermine, A. Marfaing-Koka, G. Simonneau, D. Emilie, M.
Humbert, Chemokine RANTES in severe pulmonary arterial hypertension, Am. J.
Respir. Crit. Care Med. 165 (2002) 534–539.
[127] K. Balabanian, A. Foussat, P. Dorfmuller, I. Durand-Gasselin, F. Capel, L.
Bouchet-Delbos, A. Portier, A. Marfaing-Koka, R. Krzysiek, A.-C. Rimaniol, G.Simonneau, D. Emilie, M. Humbert, CX3C chemokine fractalkine in pulmonary arte-
rial hypertension, Am. J. Respir. Crit. Care Med. 165 (2002) 1419–1425.
[128] F. Perros, P. Dorfmüller, R. Souza, I. Durand-Gasselin, V. Godot, F. Capel, S. Adnot, S.
Eddahibi, M. Mazmanian, E. Fadel, P. Hervé, G. Simonneau, D. Emilie, M. Humbert,
Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension,
Eur. Respir. J. 29 (2007) 937–943.
